Actions of nitric oxide and expression of the mRNA encoding nitric oxide synthase in rat vagal afferent neurons

European Journal of Pharmacology
A J LawrenceB Jarrott

Abstract

The present study has investigated whether nitric oxide (NO) is involved in neurotransmission of rat vagal afferent neurons. The diethylamine-NO complex (diethylamine-NO, 10-100 microM) and S-nitroso-N-acetylpenicillamine (3-100 microM) both elicited a concentration-dependent depolarisation of the isolated rat nodose ganglion preparation. Pre-treatment with 1 H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 300 nM), 6-(phenylamino)-5,8-quinolinedione (LY83,583, 30 microM) and Methylene blue (100 microM) all caused a significant shift to the right in the concentration-response curve to diethylamine-NO. Incubation of rat nodose ganglion sections with a 35S-labeled antisense oligonucleotide to neuronal NO synthase resulted in visualisation of the mRNA encoding NO synthase over vagal afferent perikarya. The anatomical findings, therefore, suggest that a number of rat vagal afferent perikarya possess the ability to produce the enzyme required for the biosynthesis of NO. Collectively, these data suggest that NO may be functionally important as a neuromodulator of rat vagal afferent neurons.

References

Jan 1, 1992·Neuron·D S Bredt, S H Snyder
Jan 1, 1992·Clinical and Experimental Hypertension. Part A, Theory and Practice·R E WiddopB Jarrott
Aug 21, 1990·European Journal of Pharmacology·R E WiddopB Jarrott
Oct 17, 1989·European Journal of Pharmacology·J GarthwaiteS Moncada
Aug 15, 1995·European Journal of Pharmacology·D LuoS R Vincent
Apr 1, 1995·British Journal of Pharmacology·A J LawrenceB Jarrott
Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·A M FranchiM Gimeno
Dec 1, 1993·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·B L ZhangJ Sassard
Jan 1, 1996·Progress in Neurobiology·A J Lawrence, B Jarrott

❮ Previous
Next ❯

Citations

Feb 13, 2001·European Journal of Pharmacology·L C AddingL E Gustafsson
Jun 5, 1997·European Journal of Pharmacology·A J LawrenceB Jarrott
Jul 4, 1998·European Journal of Pharmacology·E KrstewA J Lawrence
Nov 6, 2003·Regulatory Peptides·Daniel J Lodge, Andrew J Lawrence
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniel J Lodge, Andrew J Lawrence
Dec 19, 2000·Journal of Chemical Neuroanatomy·F O EstevesT F Batten
Mar 29, 2003·Journal of Chemical Neuroanatomy·Hung-Ming ChangJeng-Yung Shieh
Apr 3, 1999·British Journal of Pharmacology·L C AddingL E Gustafsson
Nov 26, 1999·Acta Physiologica Scandinavica·L C AddingL E Gustafsson
Oct 13, 2006·Current Opinion in Gastroenterology·T M Chang, W Y Chey
Sep 26, 2009·Journal of Chemical Neuroanatomy·Li-Hsien Lin
Jun 6, 2006·British Journal of Pharmacology·Andrew J LawrenceBrian Oldfield
May 20, 2014·Drug and Alcohol Dependence·P J RyanA J Lawrence
Dec 31, 2005·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Ana Carolina Rodrigues Dias, Eduardo Colombari
Jan 20, 2010·Pharmaceuticals·Gregers Wegener, Vallo Volke
Oct 7, 1997·Clinical and Experimental Pharmacology & Physiology·A J Lawrence

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.